Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myocardial Infarction (AMI)
Interventions
BIOLOGICAL

Cord Blood Nucleated cells

MiSaver will be administered via peripheral intravenous injection. Based on dosage, the experimental group will be divided into two subgroups: 0.5 × 10⁷ or 1.6 × 10⁷ nucleated cells per kilogram of patient body weight.

Trial Locations (3)

Unknown

Mackay Memorial Hospital Hsinchu Branch, Hsinchu

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Chung Shan Medical University Hospital Daqing Branch, Taichung

All Listed Sponsors
lead

HONYA Medical Co Ltd

INDUSTRY